Ā | Nā=ā1012 | P value | |
---|---|---|---|
Age (years) | 59āĀ±ā10 | Ā | |
Male sex, n (%) | 804 (79) | Ā | |
Obesity (BMI >30 (kg/m2); n (%)) | 178 (18) | Ā | |
BMI (kg/m2) | Males (nā=ā804) | 26.8āĀ±ā3.6 | 0.479 |
Ā | Females (nā=ā208) | 27.1āĀ±ā4.7 | |
Waist circumference (cm) | Ā | < 0.001 | |
Ā | Males (nā=ā804) | 97āĀ±ā10 | |
Ā | Females (nā=ā208) | 88āĀ±ā12 | |
Intra-abdominal fat (cm) | Ā | < 0.001 | |
Ā | Males (nā=ā804) | 9.9āĀ±ā2.6 | |
Ā | Females (nā=ā208) | 8.3āĀ±ā2.4 | |
Subcutaneous fat (cm) | Ā | < 0.001 | |
Ā | Males (nā=ā804) | 2.3āĀ±ā1.3 | |
Ā | Females (nā=ā208) | 3.0āĀ±ā1.5 | |
Type 2 diabetes, n (%) | 158 (15) | Ā | |
Metabolic syndrome, n (%)ā | 517 (51) | Ā | |
Blood pressure (mmHg) | Ā | Ā | |
Ā | Systolic | 144āĀ±ā22 | |
Ā | Diastolic | 83āĀ±ā12 | |
Smoking, n (%) | Ā | Ā | |
Ā | Never | 171 (17) | |
Ā | Ever | 464 (46) | |
Ā | Current | 377 (37) | |
Pack years smoking | 20.8 (6.4 ā 35.0) | Ā | |
Metabolic parameters | Ā | Ā | |
Cholesterol (mmol/L) | 4.9āĀ±ā1.0 | Ā | |
LDL-cholesterol (mmol/L) | 2.8āĀ±ā0.9 | Ā | |
HDL-cholesterol (mmol/L) | 1.3 (1.0 ā 1.5) | Ā | |
Triglycerides (mmol/L) | 1.5 (1.1 ā 2.1) | Ā | |
Glucose (mmol/L) | 6.3āĀ±ā1.8 | Ā | |
Insulin (mU/L) | 10.0 (7.0 ā 14.0) | Ā | |
HOMA-IR | 2.5 (1.6 ā 3.9) | Ā | |
hsCRP (mg/L) | 1.9 (0.9 ā 3.8) | Ā | |
Adiponectin (Ī¼g/ml) | 19.7 (12.5 ā 33.2) | Ā | |
eGFR (ml/min/1.73Ā m2)ā” | 77āĀ±ā18 | Ā | |
Creatinine (mmol/l) | 93āĀ±ā44 | Ā | |
History of vascular disease, n (%) | Ā | Ā | |
Cerebrovascular disease | 265 (26) | ||
Coronary artery disease | 597 (59) | Ā | |
Peripheral artery disease | 242 (24) | ||
Aneurysm of the abdominal aorta | 99 (10) | ||
Medication use, n (%) | Ā | Ā | |
Platelet-aggregation inhibitors | 766 (76) | ||
Blood pressure-lowering agents | 734 (73) | ||
Lipid-lowering agents | 685 (68) | ||
Oral anticoagulants | 78 (8) | ||
Anti-hyperglycaemic agents | 96 (10) |